Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

started using Lilly’s self-pay program for Zepbound earlier this month after a change in her insurance made her ineligible for the company’s coupon savings card. Grant has been on a GLP-1 ...

Plus, peek inside Raleigh’s newest data center, a Duke researcher reflects on her canceled federal grant amid buyouts, and ...

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention.

U.S. Bank and Bank of America cards are currently not available on CNBC Select and links have been redirected to our credit card marketplace where you can review offers from other issuers like ...

Personal and small business cards issued by U.S. Bank and Discover are currently not available on CNBC Select and links have been redirected to our credit card marketplace where you can review ...

half the $1,060 list price offered to insurers before discounts or rebates and the same price someone without insurance would pay with a Zepbound savings card. The 2.5mg vial is available at $399 ...

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk. The full data from the 751-subject SURMOUNT-5 ...